NeurAxis (NASDAQ:NRXS – Get Free Report) and Viveve Medical (NASDAQ:VIVE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.
Volatility and Risk
NeurAxis has a beta of 4.26, suggesting that its stock price is 326% more volatile than the S&P 500. Comparatively, Viveve Medical has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.
Profitability
This table compares NeurAxis and Viveve Medical’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
NeurAxis | -672.66% | N/A | -787.15% |
Viveve Medical | N/A | N/A | N/A |
Analyst Recommendations
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
NeurAxis | 0 | 0 | 0 | 0 | N/A |
Viveve Medical | 0 | 0 | 0 | 0 | N/A |
Insider & Institutional Ownership
11.8% of NeurAxis shares are owned by institutional investors. 15.2% of NeurAxis shares are owned by company insiders. Comparatively, 5.7% of Viveve Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares NeurAxis and Viveve Medical”s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
NeurAxis | $2.27 million | 7.82 | -$14.63 million | ($2.94) | -0.88 |
Viveve Medical | $6.83 million | 0.00 | -$22.03 million | N/A | N/A |
NeurAxis has higher earnings, but lower revenue than Viveve Medical.
Summary
NeurAxis beats Viveve Medical on 5 of the 8 factors compared between the two stocks.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
About Viveve Medical
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.